MS: Busting the Myths
November 16, 2022 | Advocacy, Funding, Treatments
At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]
September 14, 2022 | Advocacy, Progressive, Treatments
Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]
October 27, 2021 | Life with MS
Andrew Hodson was diagnosed with Secondary Progressive MS (SPMS) in 2008. “I probably had it for 20 years before that. A mixture of symptoms appeared then went away, including numb legs plus pins and needles. The initial diagnosis was very […]